SCHEMBL2536865

SCHEMBL2536865

C1=Nc2cccc(-c3ccccc3)c2[N]1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.36
ALDH1A1 P00352 3/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP2A6 P11509 2/20 0.35
HPGD P15428 1/20 0.35
BCL2L1 Q07817 1/20 0.35
MAPK1 P28482 1/20 0.35
METAP2 P50579 1/20 0.34
TNF P01375 1/20 0.34
MAP4K4 O95819 1/20 0.33
CSF1R P07333 1/20 0.33
FGFR1 P11362 1/20 0.33
PDGFRA P16234 1/20 0.33
LTK P29376 1/20 0.33
KDR P35968 1/20 0.33
MAPK8 P45983 1/20 0.33
CSNK1A1 P48729 1/20 0.33
LIMK1 P53667 1/20 0.33
CDK5 Q00535 1/20 0.33
ACVR1 Q04771 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3999154 0.72 IDO1 (0.39) IDO1ALDH1A1HSD17B10CYP2A6HPGD
SCHEMBL4818384 0.68 TRPA1 (0.36)
SCHEMBL4821733 0.68 CYP1A2 (0.35) ALDH1A1CYP2A6MEN1KMT2A
SCHEMBL1177457 0.68 CYP3A4 (0.35) ALDH1A1HSD17B10HPGDMEN1RAB9A
SCHEMBL5600673 0.68 IDO1 (0.36) IDO1ALDH1A1HSD17B10CYP2A6HPGD
SCHEMBL16049099 0.66 ALDH1A1 (0.46) ALDH1A1HSD17B10CYP2A6HPGDBCL2L1
SCHEMBL2863 0.65
SCHEMBL362079 0.64 KMT2A (0.36) IDO1ALDH1A1MAPK1MEN1RAB9A
SCHEMBL31290744 0.64 ALDH1A1 (0.53) ALDH1A1HSD17B10CYP2A6HPGDBCL2L1
SCHEMBL21447 0.64 ALDH1A1 (0.61) ALDH1A1HSD17B10CYP2A6HPGDBCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044070-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2011-10-25 US disclosed
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE MSD K.K. (JP) 2010-08-19 US disclosed
US-7595316-B2 Heteroaryloxy nitrogenous saturated heterocyclic derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-09-29 US disclosed
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative MSD K.K. (JP) 2006-08-10 US disclosed
EP-1642898-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178375-A1 Heteroaryloxy nitrogenous saturated heterocyclic derivative HRH3, HRH4, HCRTR2 IDO1 452/4885ALDH1A1 3756/4885HSD17B10 836/4885
US-20100210637-A1 HETEROARYLOXY NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE HRH3, HRH4, HRH2 IDO1 279/4885ALDH1A1 2837/4885HSD17B10 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.